News

Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide. In a simultaneous transaction, Orchid Chemicals

Morphotek said that it will apply its proprietary Morphodoma antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer. This

The relationship between Tekmira and Bristol-Myers Squibb builds upon earlier work conducted at Bristol-Myers Squibb using small interfering RNA (siRNA) delivery technology provided by privately held Protiva Biotherapeutics.

The intention to make the voluntary takeover offer for a cash consideration of E6.25 per share was announced on July 3, 2008. The offer period will expire on

Hoana Medical said that Kahala Nui joins a list of progressive healthcare facilities by providing the LifeBed patient vigilance system technology that tracks a patient’s or residents’ vital

Separately, Barr Laboratories entered into a settlement agreement and a supply agreement to resolve the patent litigation regarding Boehringer Ingelheim’s Aggrenox product and Duramed Pharmaceuticals, a subsidiary of

The patent is licensed exclusively to the company by the patent’s assignee, Supernus Pharmaceuticals. Based on calculations made by the US Patent and Trademark Office, the term of

The interim analysis included patients from the first 200 to complete Maestro-01 and assessed the likelihood of the study reaching its primary endpoint at the end of the

The assay is now approved to screen donated blood, plasma, organs and tissue for the three viruses in individual blood donations or in pools of up to 16